⚠️ Warnings
If an allergic reaction develops during treatment, therapy must be discontinued immediately.
Areas treated with the cream should not be covered with occlusive dressings unless strictly necessary. Local and systemic toxicity is common, particularly with prolonged, continuous use over extensive areas of broken skin, in skin folds, or under polyethylene occlusion. In children and on the face, treatment must be limited to 5 days. Long-term continuous therapy is undesirable in all patients regardless of age.
The cream must not be applied to the eyes or periorbital region because of the risk of cataract, glaucoma, mycotic ocular infection, and exacerbation of herpes.
Certain body sites, such as the groin, axillae, and perianal region, are more susceptible to striae formation during treatment with Belogent. Application to these areas must therefore be kept as brief as possible.
Do not use to treat wounds or leg ulcers.
Systemic absorption of betamethasone dipropionate may produce reversible suppression of the hypothalamic–pituitary–adrenal (HPA) axis, with the potential for glucocorticoid insufficiency after withdrawal of treatment. Cushing's syndrome may develop in some patients. Patients receiving high doses of potent corticosteroids over extensive skin areas should have HPA-axis function assessed regularly. If signs of HPA-axis suppression appear, treatment should be discontinued, the frequency of application reduced, or replaced with a less potent corticosteroid.
Recovery of HPA-axis function after dose reduction is usually rapid and complete. Rarely, symptoms of corticosteroid withdrawal similar to those seen after systemic therapy may occur.
Use in children: Children may be more susceptible than adults to topical corticosteroid-induced HPA-axis suppression and to exogenous corticosteroid effects, owing to greater absorption resulting from a higher body surface area-to-weight ratio.
Belogent cream may be used to treat diaper dermatitis only when strictly necessary.
If mycotic superinfection of the lesions occurs, additional antifungal therapy is required.
Long-term topical use of gentamicin may lead to bacterial resistance to aminoglycosides. For this reason, topical gentamicin is not recommended in immunosuppressed patients or other high-risk groups. If resistance or secondary infection develops during treatment, application of the product must be discontinued and appropriate therapy initiated.
Visual disturbance
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, referral to an ophthalmologist should be considered for evaluation of possible causes, which may include cataract, glaucoma, or rare diseases such as central serous chorioretinopathy (CSCR), which have been reported following systemic and topical corticosteroid administration.
This medicinal product contains cetostearyl alcohol, which may cause local skin reactions (e.g., contact dermatitis), and chlorocresol, which may cause allergic reactions.
